We are live on ! Find out more
GERM

Amplify Treatments, Testing and Advancements ETF
GERM

Delisted

GERM was delisted on the 5th of September, 2024.

Back to rankings

11 hedge funds and large institutions have $1.14M invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

21% less funds holding

Funds holding: 14 → 11 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

77% less capital invested

Capital invested by funds: $4.93M → $1.14M (-$3.79M)

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$133K
2
UBS Group
UBS Group
Switzerland
+$8.22K
3
IA
IFP Advisors
Florida
+$3.72K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$465

Top Sellers

Rank Fund Capital Flow
1
GBWM
Granite Bay Wealth Management
New Hampshire
-$3.63M
2
Goldman Sachs
Goldman Sachs
New York
-$203K
3
HI
Harbour Investments
Wisconsin
-$34.2K
4
Citadel Advisors
Citadel Advisors
Florida
-$4.07K
5
Morgan Stanley
Morgan Stanley
New York
-$88
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$761K +$133K +7,173 +21%
Citadel Advisors
2
Citadel Advisors
Florida
$298K -$4.07K -219 -1%
FDCDDQ
3
Federation des caisses Desjardins du Quebec
Quebec, Canada
$27.4K – – –
UBS Group
4
UBS Group
Switzerland
$18.2K +$8.22K +442 +81%
IA
5
IFP Advisors
Florida
$7.44K +$3.72K +200 +100%
CHC
6
City Holding Co
West Virginia
$7.36K – – –
Osaic Holdings
7
Osaic Holdings
Arizona
$7.25K – – –
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$5.7K – – –
TAM
9
Tucker Asset Management
Colorado
$4.25K – – –
SPIA
10
Steward Partners Investment Advisory
New York
$2.94K – – –
GBWM
11
Granite Bay Wealth Management
New Hampshire
– -$3.63M -208,415 Closed
Goldman Sachs
12
Goldman Sachs
New York
– -$203K -10,372 Closed
HI
13
Harbour Investments
Wisconsin
– -$34.2K -1,750 Closed
Morgan Stanley
14
Morgan Stanley
New York
– -$88 -4 Closed
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
– +$465 +25 New

GERM Hedge Fund Activity: Q1 2024 in Review

11 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q1 2024, worth a combined $1.14M — down 77% from $4.93M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GERM and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, adding an estimated $133K. The largest seller was Granite Bay Wealth Management, exiting entirely with an estimated $3.63M sold.

  • 11 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q1 2024, down from 14 in Q4 2023.
  • Funds reported $1.14M of Amplify Treatments, Testing and Advancements ETF stock for Q1 2024, down 77% quarter-over-quarter.
  • 1 fund opened new Amplify Treatments, Testing and Advancements ETF positions in Q1 2024 and 4 closed out, a net change of -3 holders.
  • The largest Amplify Treatments, Testing and Advancements ETF buyer in Q1 2024 was Susquehanna International Group, an estimated $133K added.
  • The largest Amplify Treatments, Testing and Advancements ETF seller in Q1 2024 was Granite Bay Wealth Management, an estimated $3.63M sold.

Based on aggregated 13F filings for Q1 2024.